Cargando…
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
BACKGROUND: HER2 targeted therapies including trastuzumab and more recently lapatinib have significantly improved the prognosis for HER2 positive breast cancer patients. However, resistance to these agents is a significant clinical problem. Although several mechanisms have been proposed for resistan...
Autores principales: | McDermott, Martina SJ, Browne, Brigid C, Conlon, Neil T, O’Brien, Neil A, Slamon, Dennis J, Henry, Michael, Meleady, Paula, Clynes, Martin, Dowling, Paul, Crown, John, O’Donovan, Norma |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230643/ https://www.ncbi.nlm.nih.gov/pubmed/24958351 http://dx.doi.org/10.1186/1476-4598-13-157 |
Ejemplares similares
-
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
por: McDermott, Martina S. J., et al.
Publicado: (2023) -
HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells
por: McDermott, Martina S. J., et al.
Publicado: (2019) -
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013) -
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL
por: Eustace, Alex J, et al.
Publicado: (2018) -
Identification of pancreatic cancer invasion-related proteins by proteomic analysis
por: Walsh, Naomi, et al.
Publicado: (2009)